These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 26239362)
1. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Bhattacharyya J; Bellucci JJ; Weitzhandler I; McDaniel JR; Spasojevic I; Li X; Lin CC; Chi JT; Chilkoti A Nat Commun; 2015 Aug; 6():7939. PubMed ID: 26239362 [TBL] [Abstract][Full Text] [Related]
2. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490 [TBL] [Abstract][Full Text] [Related]
3. Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane. Zhao M; Li H; Bu X; Lei C; Fang Q; Hu Z ACS Nano; 2015 Oct; 9(10):10099-112. PubMed ID: 26324059 [TBL] [Abstract][Full Text] [Related]
4. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Yuan H; Guo H; Luan X; He M; Li F; Burnett J; Truchan N; Sun D Mol Pharm; 2020 Jul; 17(7):2275-2286. PubMed ID: 32485107 [TBL] [Abstract][Full Text] [Related]
5. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Xiao K; Luo J; Fowler WL; Li Y; Lee JS; Xing L; Cheng RH; Wang L; Lam KS Biomaterials; 2009 Oct; 30(30):6006-16. PubMed ID: 19660809 [TBL] [Abstract][Full Text] [Related]
6. Reduction-Responsive and Multidrug Deliverable Albumin Nanoparticles: An Antitumor Drug to Abraxane against Human Pancreatic Tumor-Bearing Mice. Hirakawa N; Ishima Y; Kinoshita R; Nakano R; Chuang VTG; Ando H; Shimizu T; Okuhira K; Maruyama T; Otagiri M; Ishida T ACS Appl Bio Mater; 2021 May; 4(5):4302-4309. PubMed ID: 35006842 [TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Feng Z; Zhao G; Yu L; Gough D; Howell SB Cancer Chemother Pharmacol; 2010 Apr; 65(5):923-30. PubMed ID: 19685054 [TBL] [Abstract][Full Text] [Related]
8. Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models. Banskota S; Saha S; Bhattacharya J; Kirmani N; Yousefpour P; Dzuricky M; Zakharov N; Li X; Spasojevic I; Young K; Chilkoti A Nano Lett; 2020 Apr; 20(4):2396-2409. PubMed ID: 32125864 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®. Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929 [TBL] [Abstract][Full Text] [Related]
10. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978 [TBL] [Abstract][Full Text] [Related]
11. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug. Battogtokh G; Kang JH; Ko YT Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785 [TBL] [Abstract][Full Text] [Related]
12. Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. Zhao M; Lei C; Yang Y; Bu X; Ma H; Gong H; Liu J; Fang X; Hu Z; Fang Q PLoS One; 2015; 10(7):e0131429. PubMed ID: 26182353 [TBL] [Abstract][Full Text] [Related]
13. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144 [TBL] [Abstract][Full Text] [Related]
14. Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel. Ruttala HB; Ramasamy T; Shin BS; Choi HG; Yong CS; Kim JO Int J Pharm; 2017 Mar; 519(1-2):11-21. PubMed ID: 28069389 [TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models. Chen H; Huang S; Wang H; Chen X; Zhang H; Xu Y; Fan W; Pan Y; Wen Q; Lin Z; Wang X; Gu Y; Ding B; Chen J; Wu X Drug Deliv; 2021 Dec; 28(1):1067-1079. PubMed ID: 34109887 [TBL] [Abstract][Full Text] [Related]
16. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391 [TBL] [Abstract][Full Text] [Related]
17. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Karmali PP; Kotamraju VR; Kastantin M; Black M; Missirlis D; Tirrell M; Ruoslahti E Nanomedicine; 2009 Mar; 5(1):73-82. PubMed ID: 18829396 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524 [TBL] [Abstract][Full Text] [Related]
19. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494 [TBL] [Abstract][Full Text] [Related]
20. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer. Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]